An Update on Therapy of Primary Central Nervous System Lymphoma

The most important advance in primary central nervous system (CNS) lymphoma treatment has been the convincing data that high-dose methotrexate-based chemotherapy regimens improve survival compared to historical controls treated with radio-therapy alone. However, the optimal treatment ap-proach is still unclear and therapy can be associated with long-term neurotoxicity. Current research focuses on maximizing survival while minimizing neurologic sequelae. Primary central nervous system lymphoma (PCNSL) is an extranodal non-Hodgkin lymphoma (NHL) that arises from the brain parenchyma, eyes, meninges or spinal cord in the absence of systemic disease. Recent clinical trials have focused increased interest on this cancer